Citizens Financial Group Inc. RI Has $2.03 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Citizens Financial Group Inc. RI raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,618 shares of the biopharmaceutical company’s stock after buying an additional 959 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Regeneron Pharmaceuticals were worth $2,034,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC raised its position in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at approximately $226,000. Everpar Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 15.9% in the 2nd quarter. Everpar Advisors LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 71 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Regeneron Pharmaceuticals by 112.2% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 8,842 shares of the biopharmaceutical company’s stock worth $4,642,000 after buying an additional 4,676 shares in the last quarter. Finally, Czech National Bank raised its holdings in shares of Regeneron Pharmaceuticals by 5.0% in the 2nd quarter. Czech National Bank now owns 25,384 shares of the biopharmaceutical company’s stock worth $13,327,000 after buying an additional 1,220 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. UBS Group upped their price target on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. HSBC started coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price target for the company. Finally, Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $791.05.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $758.91 on Wednesday. The stock has a 50-day simple moving average of $743.26 and a 200 day simple moving average of $632.97. The stock has a market capitalization of $79.76 billion, a price-to-earnings ratio of 18.17, a P/E/G ratio of 2.01 and a beta of 0.39. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter last year, the company posted $12.46 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 8,431 shares of company stock worth $5,733,521. Insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.